Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model

BACKGROUND: Patients with stable coronary artery disease (CAD) constitute a heterogeneous group in which the treatment benefits by angiotensin‐converting enzyme (ACE)‐inhibitor therapy vary between individuals. Our objective was to integrate clinical and pharmacogenetic determinants in an ultimate c...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Am Heart Assoc
Auteurs principaux: Oemrawsingh, Rohit M., Akkerhuis, K. Martijn, Van Vark, Laura C., Redekop, W. Ken, Rudez, Goran, Remme, Willem J., Bertrand, Michel E., Fox, Kim M., Ferrari, Roberto, Danser, A.H. Jan, de Maat, Moniek, Simoons, Maarten L., Brugts, Jasper J., Boersma, Eric
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2016
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4943245/
https://ncbi.nlm.nih.gov/pubmed/27021566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.115.002688
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires